Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02241369 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02241369 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT02241369, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 DNA vaccines delivered by Electroporation to subjects with HPV6 associated aerodigestive precancerous lesions and malignancies.
Interventions
- BIOLOGICAL INO-3106, INO-9012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02241369
The ClinicalTrials.gov registry entry for NCT02241369 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INO-3106, INO-9012 is the first listed.
NCT02241369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02241369 about?
NCT02241369 is a clinical study titled "Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies". This is a Phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 DNA vaccines delivered by Electroporation to subjects with HPV6 associated aerodigestive precancerous lesions and malignancies.
What is the current status of trial NCT02241369?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-05. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02241369?
The interventions under investigation include: INO-3106, INO-9012 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02241369?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.